An observational study in Age Related Macular Degeneration, Geographic Atrophy and AMD, sponsored by Center for Eye Research Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Center for Eye Research Australia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Geographic Atrophy with a site in Australia — 12 open to participants now, 15 under way, 4 of them phase 3. Geographic Atrophy · Australia.
Among the 41 studies in Geographic Atrophy with a site in Australia, this one is one of 5 that started in 2021, is one of 7 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 23rd registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →12 of the 41 studies in Geographic Atrophy with a site in Australia are open now. Recruiting first, the newest first:
Biojiva LLC · Sites in Australia, United States
Ages 55+
Sitala Bio LTD · Sites in Australia, United States, Argentina and 4 more countries
Ages 60+
Theratocular Biotek Co. · Sites in Australia
Ages 50+
Novartis Pharmaceuticals · Sites in Australia, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Australia, United States, Austria and 9 more countries
Ages 60+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 14 · Phase 4 1
First in 2014; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 130 across 39 observational studies indexed under Geographic Atrophy.
Median enrollment 280 across the 34 interventional studies, 255 across the 7 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 41 have an industry lead sponsor. The 10 most frequent:
Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Center for Eye Research Australia has 1 study filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
6 of the studies in Geographic Atrophy with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06662162i-Lumen Scientific AUS PTY LTDMicrocurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration | 2027-03-31 |
| NCT07668804Theratocular Biotek Co.A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy | 2027-08-31 |
| NCT06087458Perceive Biotherapeutics, Inc.Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 41 studies in Geographic Atrophy with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 130 across 39 observational studies indexed under Geographic Atrophy.
Browse Geographic Atrophy studies →Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
People in Australia aged 18 years or older with AMD or healthy controls, willing and able to provide informed consent, and willing to accept the study requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Age-Related Macular Degeneration
Other: N/A Observational study
N/A Observational study
Investigate the underlying aetiology of Age-Related Macular Degeneration
The first aim of this project is to comprehensively investigate the underlying aetiology of AMD, characterise the AMD phenotype by understanding the differences between those with AMD and healthy individuals.
Time frame: Up to 20 years
Characterise the natural history of Age-Related Macular Degeneration and factors associated with its rate of progression.
The second aim of this project is to characterise the natural history of AMD and factors associated with its rate of progression. These aims will be achieved by using performing imaging and functional assessment of the retina, characterisation of the genetic, systemic and environmental factors, and by obtaining patient-reported outcomes.
Time frame: Up to 20 years
Plan to share: Yes — All collected IPD at the discretion of the Principal Investigator in a de-identified format
Started Feb 2021 (actual). Primary completion is estimated for Nov 2040, 237 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Eye Research Australia